SG11201700094TA - Treatment of leukemia with histone deacetylase inhibitors - Google Patents
Treatment of leukemia with histone deacetylase inhibitorsInfo
- Publication number
- SG11201700094TA SG11201700094TA SG11201700094TA SG11201700094TA SG11201700094TA SG 11201700094T A SG11201700094T A SG 11201700094TA SG 11201700094T A SG11201700094T A SG 11201700094TA SG 11201700094T A SG11201700094T A SG 11201700094TA SG 11201700094T A SG11201700094T A SG 11201700094TA
- Authority
- SG
- Singapore
- Prior art keywords
- leukemia
- treatment
- histone deacetylase
- deacetylase inhibitors
- inhibitors
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462021473P | 2014-07-07 | 2014-07-07 | |
US201462061233P | 2014-10-08 | 2014-10-08 | |
US201562147218P | 2015-04-14 | 2015-04-14 | |
PCT/US2015/039225 WO2016007423A1 (en) | 2014-07-07 | 2015-07-06 | Treatment of leukemia with histone deacetylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700094TA true SG11201700094TA (en) | 2017-02-27 |
Family
ID=55064739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700094TA SG11201700094TA (en) | 2014-07-07 | 2015-07-06 | Treatment of leukemia with histone deacetylase inhibitors |
Country Status (13)
Country | Link |
---|---|
US (1) | US9833466B2 (ja) |
EP (1) | EP3166603B1 (ja) |
JP (1) | JP6952602B2 (ja) |
KR (1) | KR20170044097A (ja) |
CN (1) | CN107205988A (ja) |
AU (1) | AU2015288060A1 (ja) |
BR (1) | BR112017000301A2 (ja) |
CA (1) | CA2954522A1 (ja) |
EA (1) | EA201790142A1 (ja) |
IL (1) | IL249935A0 (ja) |
MX (1) | MX2017000307A (ja) |
SG (1) | SG11201700094TA (ja) |
WO (1) | WO2016007423A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
US9663825B2 (en) | 2012-04-19 | 2017-05-30 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
JP6626437B2 (ja) * | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
EP4137135B1 (en) | 2013-10-24 | 2024-06-05 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
CN107835810A (zh) | 2014-12-12 | 2018-03-23 | 瑞格纳西制药有限公司 | 作为hdac1/2抑制剂的哌啶衍生物 |
EP3286310A4 (en) * | 2015-04-24 | 2019-01-09 | California Institute of Technology | REACTIVATION OF X-CHROMOSOME GENES |
CA2988594C (en) | 2015-06-08 | 2023-08-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
US10464906B2 (en) | 2015-06-08 | 2019-11-05 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
JP2019515909A (ja) * | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 |
JP7233220B2 (ja) * | 2016-06-09 | 2023-03-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Hdac阻害剤とbet阻害剤の使用方法及びその薬学的組み合わせ |
WO2018031472A1 (en) | 2016-08-08 | 2018-02-15 | Acetylon Pharmaceuticals Inc. | Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof |
WO2018081661A1 (en) | 2016-10-27 | 2018-05-03 | California Institute Of Technology | Hdac inhibitor compositions for reactivation of the x chromosome |
JP7090611B2 (ja) | 2016-11-23 | 2022-06-24 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド1(pd-l1)阻害剤とを含む医薬組み合わせ物及びその使用方法 |
CN106810460A (zh) * | 2016-12-30 | 2017-06-09 | 苏州诚和医药化学有限公司 | 一种4‑[2‑(二甲基氨基)乙氧基]苄胺的制备方法 |
WO2019084434A1 (en) | 2017-10-26 | 2019-05-02 | National University Of Singapore | NEW APPROACH FOR UNIVERSAL MONITORING OF MINIMUM RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA |
JP7021503B2 (ja) * | 2017-11-02 | 2022-02-17 | 三菱瓦斯化学株式会社 | 脂肪族ジアミンの製造方法 |
WO2023134707A1 (en) * | 2022-01-11 | 2023-07-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating aml-mrc and mds |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US20050119305A1 (en) | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
EA007578B1 (ru) | 2001-11-01 | 2006-12-29 | Янссен Фармацевтика Н.В. | Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета |
DK1485354T3 (da) | 2002-03-13 | 2008-09-01 | Janssen Pharmaceutica Nv | Sulfonylamino-derivater som nye inhibitorer af histandeacetylase |
AU2003212335B8 (en) | 2002-03-13 | 2009-04-23 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2005012261A1 (de) | 2003-07-24 | 2005-02-10 | Basf Aktiengesellschaft | 2-substituierte pyrimidine |
US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
US7868205B2 (en) | 2003-09-24 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP4993374B2 (ja) | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
CA2620414A1 (en) | 2005-08-26 | 2007-03-01 | Methylgene Inc. | Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase |
EP1950208B1 (en) | 2005-11-01 | 2012-05-02 | Sumitomo Chemical Company, Limited | Process for producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one |
PL1981877T3 (pl) | 2006-02-07 | 2012-12-31 | Astellas Pharma Inc | Związki N-hydroksyakryloamidowe |
WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
AU2007234843B2 (en) | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
AU2007243519A1 (en) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
US20100278782A1 (en) | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
JP5563300B2 (ja) | 2006-09-11 | 2014-07-30 | キュリス,インコーポレイテッド | 亜鉛結合部分を含むチロシンキナーゼインヒビター |
WO2008055068A2 (en) | 2006-10-28 | 2008-05-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
EA017198B1 (ru) | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
JP2010519287A (ja) | 2007-02-21 | 2010-06-03 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | α−ハロシクロプロピルカルボキシ化合物およびα−アルキルシクロプロピルカルボキシ化合物ならびにそれらの使用 |
JP2010120852A (ja) | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | 新規なジアミド誘導体 |
WO2009033281A1 (en) | 2007-09-14 | 2009-03-19 | Methylgene Inc. | Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer |
US8778410B2 (en) | 2008-02-19 | 2014-07-15 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
RS54230B1 (en) | 2009-01-08 | 2015-12-31 | Curis Inc. | 3-KINASE PHOSPHOINOSITIDE INHIBITORS WITH ZINC BINDING PART |
JP5713999B2 (ja) | 2009-05-15 | 2015-05-07 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | アミド化合物、その製造方法及びそれを含む薬学組成物 |
EP2456757B1 (en) | 2009-07-22 | 2019-05-01 | The Board of Trustees of the University of Illionis | Hdac inhibitors and therapeutic methods using the same |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
EP2638009A4 (en) | 2010-01-08 | 2014-06-11 | Harvard College | FLUORINATED HDAC HEMMER AND USES THEREOF |
LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
CA2800143A1 (en) | 2010-05-21 | 2011-11-24 | The Trustees Of Columbia University In The City Of New York | Selective hdac inhibitors |
WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
US8859502B2 (en) * | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
PL2640709T3 (pl) | 2010-11-16 | 2016-10-31 | Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania” | |
US8404738B2 (en) | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
WO2013013113A2 (en) | 2011-07-20 | 2013-01-24 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
US9663825B2 (en) | 2012-04-19 | 2017-05-30 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
WO2014121062A1 (en) | 2013-02-01 | 2014-08-07 | Acetylon Pharmaceuticals, Inc. | Selective hdac3 inhibitors |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
EP3004141A4 (en) | 2013-06-03 | 2017-05-31 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
WO2015054197A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
WO2015054175A1 (en) | 2013-10-11 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
WO2015095632A1 (en) | 2013-12-20 | 2015-06-25 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2015
- 2015-07-06 BR BR112017000301A patent/BR112017000301A2/pt not_active Application Discontinuation
- 2015-07-06 AU AU2015288060A patent/AU2015288060A1/en not_active Abandoned
- 2015-07-06 JP JP2017522324A patent/JP6952602B2/ja active Active
- 2015-07-06 WO PCT/US2015/039225 patent/WO2016007423A1/en active Application Filing
- 2015-07-06 EP EP15818585.0A patent/EP3166603B1/en active Active
- 2015-07-06 EA EA201790142A patent/EA201790142A1/ru unknown
- 2015-07-06 US US14/792,046 patent/US9833466B2/en active Active
- 2015-07-06 KR KR1020177003321A patent/KR20170044097A/ko unknown
- 2015-07-06 CN CN201580047830.2A patent/CN107205988A/zh active Pending
- 2015-07-06 CA CA2954522A patent/CA2954522A1/en not_active Abandoned
- 2015-07-06 MX MX2017000307A patent/MX2017000307A/es unknown
- 2015-07-06 SG SG11201700094TA patent/SG11201700094TA/en unknown
-
2017
- 2017-01-05 IL IL249935A patent/IL249935A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2017000307A (es) | 2017-11-23 |
CN107205988A (zh) | 2017-09-26 |
US20160030458A1 (en) | 2016-02-04 |
EP3166603B1 (en) | 2020-02-12 |
EP3166603A1 (en) | 2017-05-17 |
CA2954522A1 (en) | 2016-01-14 |
IL249935A0 (en) | 2017-03-30 |
KR20170044097A (ko) | 2017-04-24 |
JP6952602B2 (ja) | 2021-10-20 |
EP3166603A4 (en) | 2017-12-13 |
WO2016007423A1 (en) | 2016-01-14 |
AU2015288060A1 (en) | 2017-02-09 |
US9833466B2 (en) | 2017-12-05 |
EA201790142A1 (ru) | 2017-07-31 |
JP2017524735A (ja) | 2017-08-31 |
BR112017000301A2 (pt) | 2017-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL249935A0 (en) | Treatment of leukemia with histone deacetylase inhibitors | |
IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
PL3319959T3 (pl) | Hetero-haloinhibitory deacetylazy histonowej | |
ZA201604272B (en) | Inhibitors of glutaminase | |
IL246902A0 (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
IL249629A0 (en) | Histone demethylase inhibitors | |
IL263360A (en) | Combinations comprising histone deacetylase inhibitors | |
IL251103A0 (en) | Histone demethylase inhibitors | |
IL249339A0 (en) | Histone deacetylase inhibitors and compositions and methods of using them | |
EP3129373A4 (en) | Histone deacetylase inhibitors | |
IL251179A0 (en) | Histone demethylase inhibitors | |
IL267465A (en) | Histone deacetylase inhibitors | |
IL256438B (en) | Histone deacetylase inhibitors | |
IL251184A0 (en) | Histone demethylase inhibitors |